Australia markets close in 4 hours 7 minutes

ResMed Inc. (RMD)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
180.72+6.11 (+3.50%)
At close: 04:00PM EST
180.72 0.00 (0.00%)
After hours: 07:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous close174.61
Open176.20
Bid177.01 x 900
Ask181.50 x 900
Day's range175.21 - 181.18
52-week range132.24 - 243.52
Volume1,049,353
Avg. volume899,960
Market cap26.582B
Beta (5Y monthly)0.65
PE ratio (TTM)29.92
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.92 (1.10%)
Ex-dividend date07 Feb 2024
1y target estN/A
  • GlobeNewswire

    ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

    Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapyPart of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two l

  • GlobeNewswire

    MatrixCare Earns Three 2024 Best in KLAS Awards

    MatrixCare has been named a market leader by KLAS Research for its Home Health EHR in three Categories: Home Health – Independent – Large, Home Health – Independent – Small, and Hospice – IndependentBLOOMINGTON, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a global technology leader in the post-acute space, is proud to announce its Home Health and Hospice EHR solution was named Best in KLAS across multiple categories according to the 2024 Best in KLAS Software and Services report. Home H

  • GlobeNewswire

    ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

    Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20%Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023. Second Quarter 2024 HighlightsAll comparisons are to the prior year period Re